STAT4 and systemic lupus erythematosus: In addition, carriers of the risk allele exhibit exaggerated CD4+ T-cell activation that, in the context of SLE, contribute to more severe disease, and R/R patients may benefit from blockade of the IL-12/STAT4 pathway (50).